自身免疫性肝炎患者的糖尿病:频率、危险因素及对结局的影响
该回顾性/前瞻性单中心研究纳入1987-2023年494例自身免疫性肝炎(AIH)患者,466例接受糖皮质激素治疗。47例(10%)在AIH诊断时已有糖尿病,另59例(13%)新发糖尿病。新发糖尿病与年龄较大、非白种人、初始泼尼松龙剂量较高、诊断时BMI较高及随访2年后体重增加独立相关,且为全因死亡/移植和肝硬化的独立预测因素。
要点
- AIH诊断时10%患者已有糖尿病,随访中新发糖尿病占13%。
- 接受泼尼松龙者新发糖尿病1年累积发生率8%±1%,10年14%±2%。
- 新发糖尿病为全因死亡/移植和肝硬化的独立预测因素。
核心结论
- 新发糖尿病发生于13%的AIH患者,与年龄较大、非白种人、泼尼松龙剂量较高、诊断时BMI较高及体重增加相关。
- 新发糖尿病是全因死亡/移植和肝硬化发生的独立预测因素,强调需尽量减少AIH患者的激素负担。
研究设计与样本
- 回顾性/前瞻性单中心研究,纳入1987-2023年494例AIH患者,其中466例接受糖皮质激素治疗(454例泼尼松龙,12例布地奈德),中位随访9年(范围0-36年)。
主要发现
- 47例(10%)在AIH诊断时已有糖尿病,另59例(13%)随后新发糖尿病。
- 接受泼尼松龙者新发糖尿病1年累积发生率为8%±1%,10年为14%±2%(分别为预期人群率的14倍和3倍)。
- 新发糖尿病通常持续存在,即使停用泼尼松龙。
- 新发糖尿病和任何时间糖尿病均与全因死亡/移植率独立相关,同时与已知危险因素(年龄较大、肝硬化、诊断时ALT较低及早期ALT未正常化)相关。
- 新发糖尿病和任何时间糖尿病亦与肝硬化发生独立相关;与肝病相关死亡/移植的关联仅单因素分析显著,多因素分析不显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment for autoimmune hepatitis (AIH) includes corticosteroids, which are associated with the development of diabetes mellitus (DM). Reported new-onset DM rates in patients with AIH have varied, and predisposing factors and prognostic implications are inadequately characterised. AIM: To identify the frequency and predisposing factors for DM in AIH and its association with disease progression and mortality. METHODS: Retrospective/prospective single-centre study of 494 patients with AIH presenting 1987-2023, 466 receiving corticosteroids (454 prednisolone, 12 budesonide) and followed for (median (range) 9 (0-36) years). RESULTS: Forty-seven patients (10%) already had DM at AIH diagnosis. New-onset DM subsequently developed in another 59 (13%). In those receiving prednisolone, new-onset DM incidence was 8% ± 1% after 1 year and 14% ± 2% after 10 years (14- and 3-fold higher than expected population rate), and was independently associated with older age, non-Caucasian ethnicity, higher initial prednisolone dose, higher BMI at diagnosis and more weight gain after 2 years of follow-up. New-onset DM usually persisted despite stopping prednisolone. New-onset DM and DM at any time were independently associated with all-cause death/transplantation rate, along with previously established risk factors (older age, cirrhosis, lower ALT at diagnosis and failure of early ALT normalisation). New-onset DM and DM at any time were also independently associated with cirrhosis development. Similar associations of new-onset DM and DM at any time with liver-related death/transplantation were significant on univariate but not multivariate analysis. CONCLUSION: New-onset DM occurred in 13% of patients with AIH, was related to older age, non-Caucasian ethnicity, higher prednisolone dose, higher BMI at diagnosis and weight gain; and was an independent predictor of all-cause death/transplantation and of cirrhosis development, underlining the need to minimise steroid burden in AIH.
引用
- Flatley S, Dixon S, Pilsworth E, et al. Diabetes Mellitus in Patients With Autoimmune Hepatitis: Frequency, Risk Factors and Effect on Outcome. Aliment Pharmacol Ther. 2025. PMID: 40342076. doi:10.1111/apt.70188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。